Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET

Company Participants

Alex Dasalla - Head, IR

Joseph Ciaffoni - CEO

Colleen Tupper - CFO

Scott Dreyer - CCO

Conference Call Participants

Greg Fraser - Truist

David Amsellem - Piper Sandler

Serge Belanger - Needham & Company

Tim Lugo - William Blair

Operator

Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2022 Earnings Call. [Operator Instructions] Please note that this conference is being recorded.

I will now turn the conference over to our host, Alex Dasalla, Head of Investor Relations. Thank you. You may begin.

Alex Dasalla

Welcome to Collegium Pharmaceutical's Second Quarter 2022 Earnings Conference Call. This is Alex Dasalla, Head of Investor Relations for Collegium. I am joined today by Joe Ciaffoni, our Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.

Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to derive the expected benefits of the acquisition of BioDelivery Sciences International on the proposed schedule or at all, that we may not be able to successfully renegotiate our contracts related to Xtampza ER prescriptions on desired terms, that we may not be able to successfully commercialize our products and that we may incur significant expense and may not prevail in current or future patent infringement litigation or other litigation pertaining to our products.

These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today.

Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations on our corporate website at collegiumpharma.com.

I will now turn the call over to Collegium's CEO, Joe Ciaffoni.

Joseph Ciaffoni

Thank you, Alex. Good afternoon, and thank you, everyone, for joining the call. Today, we will discuss our performance during Q2 and the first half of 2022 and provide some perspective on our outlook for the remainder of the year. At Collegium, we remain focused on our mission to build a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions.